Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity

Tsanangudzo Pfupi

Kemikari Zita: Lasofoxifene Tartrate

CAS: 190791-29-8

Chitarisiko: Muchena kusvika Kuchena-Upfu

Chiral Purity: ≥99.0%Kuchena: ≥98.0% (HPLC)

Mukurapa kwePostmenopausal Osteoporosis

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Tumira email kwatiri

Product Detail

Product Tags

Tsanangudzo:

Mugadziri Wekutengesa ane Kuchena Kwepamusoro uye Hunhu Hwakagadzikana
Kemikari Zita: Lasofoxifene Tartrate
CAS: 190791-29-8
Lasofoxifene Tartrate (CAS: 190791-29-8) mukurapa kwePostmenopausal Osteoporosis

Chemical Properties:

Chemical Name	Lasofoxifene tartrate
Mashoko anoreva zvakafanana	(5R,6S) -5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl) ethoxy]phenyl] -2-naphthalenol Tartrate Oporia
Nhamba yeCAS	190791-29-8
Nhamba yeCAT	RF-API20
Stock Status	MuStock, Kugadzirwa Kunokwira Kusvika Mazana emaKilogram
Molecular Formula	C28H31NO2.ClH
Molecular Weight	450.019
Brand	Ruifu Chemical

Zvinotsanangurwa:

Item	Zvinotsanangurwa
Chitarisiko	Ichena kusvika kuOff-White Powder
Kunyorova (KF)	≤0.50%
Heavy Metals	≤20ppm
Chiral Purity	≥99.0%
Kuchena / Analysis Method	≥98.0% (HPLC)
Kurasika paKuomesa	≤0.50%
Residue paIgnition	≤0.50%
Test Standard	Chinese Pharmacopoeia (CP);Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API);Postmenopausal Osteoporosis

Package & Kuchengeta:

Package: Bhodhoro, Aluminium foil bag, Cardboard dhiramu, 25kg/Drum, kana zvinoenderana nezvinodiwa nemutengi.

Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza, mwando uye tumbuyu.

Zvakanakira:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. ndiyo inotungamira mugadziri uye mutengesi weLasofoxifene Tartrate (CAS: 190791-29-8) ine mhando yepamusoro.
Lasofoxifene Tartrate ndeyechitatu-chizvarwa, isiri-steroidal inosarudza estrogen receptor modulator (SERM).Iyo inosarudza inosunga kumunhu ERalpha ine IC50 kukosha kwe1.5 nM uye inhibits kurasikirwa kwemapfupa mumakonzo ane ovariectomized.Muzvidzidzo zvemakiriniki zve postmenopausal osteoporosis, 0.5 mg / zuva lasofoxifene yakabatanidzwa nenjodzi dzakaderedzwa dze nonvertebral uye vertebral fractures, ER-positive kenza yemazamu, chirwere chemwoyo, uye sitiroko asi kuwedzera kwengozi yezviitiko zvevenous thromboembolic.Lasofoxifene yakaratidzawo kuita seanverse agonist paCB2 cannabinoid receptor, zvichiratidza kugona kwayo kudzokororwa semushonga wezviratidzo umo CB2 inotarisirwa.